Kite, A Gilead Company

This study tested a treatment called KTE-X19 (a type of CAR T-cell therapy) in 105 adults with mantle cell lymphoma that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better attack the cancer…

This study tested a treatment called KTE-X19, which uses a patient's own immune cells that are modified in a lab to better attack cancer. It involved 95 children and teens whose B-cell leukemia or lymphoma had returned or stopped responding to standard treatments. The goal was to…

This study tested a cancer treatment called axicabtagene ciloleucel (a CAR T-cell therapy) given with preventive steroids to 35 adults with large B-cell lymphoma that had returned or not responded to prior treatments. The goal was to see if giving the therapy in an outpatient set…

This study tested a personalized cell therapy (axicabtagene ciloleucel) against standard treatments in 359 adults with relapsed or refractory diffuse large B-cell lymphoma. The therapy uses a patient's own immune cells, modified to attack cancer. Results showed improved event-fre…

This study tested a one-time treatment called KTE-X19 (a CAR T-cell therapy) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior therapies. The main goal was to see how many patients had their tumors shrink or disappear. Participants received t…

This study tested a one-time treatment using a person's own immune cells, modified to attack cancer, in 159 adults with follicular or marginal zone lymphoma that had returned after at least two prior therapies. The main goal was to see how many patients had their tumors shrink or…